

Horumarinta helitaanka daaweynta kansarka ee badbaadisa nolosha.

Maarso 07, 2025 Weydiimaha warbaahinta ([Media inquiries](#))

Dowladda Alberta waxay horumarinaysaa helitaanka daaweynta kansarka qanjirka ee heerka sare ah iyada oo dadweynaha Alberta loo sameynaayo dawo cusub oo casri ah.

Alberta gudaheeda, qiyaastii 2,500 oo rag ah ayaa sannad kasta laga helaa kansarka qanjirka prostateka, iyadoo hal nin oo lixdii nin ee gobolka ku nool ah uu la kulmo cudurka inta uu nool yahay.

Dadka reer Alberta ee la nool kansarka waxay u baahan yihiin daaweymo waxtar leh oo casri ah. Taasi waa sababta ay dowladda Alberta uga go'an tahay maalgelinta daawaynta cusub si loo horumariyo daryeelka kansarka iyo ka hortaggiisa.

Si loo taageero dadaalladan, dowladda Alberta waxay ka dhigtay Pluvicto oo ah daaweyn cusub oo raadiyofarmasiyuutik ah oo loogu talagalay kansarka prostate-ka ee heerka sare ah mid laga heli karo dadka reer Alberta.

“Waxaan ognahay in dadka reer Alberta ee la nool kansarka prostate-ka ee heerka sare ah iyo bixiyeyaasha daryeelkooda caafimaad ay sugayeen helitaanka daawayntan cusub. Keenista Pluvicto gobolka Alberta waxay ahayd mudnaan dowladda, waxaana aad ugu faraxsanahay inaan hadda u heli karno daawayntan casriga ah dadka reer Alberta.”

Adriana LaGrange, Wasiirka Caafimaad

Markii heshiis qaran oo la xiriira qiimaha dawada la gaaray bishii Diseembar 2024, Alberta waxay si degdeg ah ugu dartay Pluvicto liiska daawooyinka kansarka ee bukaannada baxnaaninta helaan, iyadoo noqotay gobolka saddexaad ee sidaas sameeya, oo ay weheliyaan Ontario iyo Nova Scotia. Alberta Health Services ayaa hadda dhammaystiraysa heshiis lala galayo soo saaraha si loo hubiyo in daawayntan ay si fudud u heli karaan bukaannada.

Barnaamijka Faa'iidada Daawada Kansarka ee Bukaannada Baxnaaninta wuxuu bixiyaa helitaanka daawooyinka kansarka ee ku jira liiska, iyadoo aan wax kharash ah laga qaadin bukaannada.

Kahor intaan daawayntan la bixin, gobolka wuxuu diyaariyey dhammaan nidaamyada gaarka ah ee loo baahan yahay, sida maaraynta, isticmaalka, iyo sawirrada caafimaad ee la xiriira, iyo sidoo kale tababarka bixiyeyaasha daryeelka caafimaadka. Waxaa la filayaa in daawaynta Pluvicto, oo ah daawayn raadiyofarmasiyuutik ah oo la siiyo xariiq duritaan ah, ay bilaabato in la siiyo dadka reer Alberta dabayaaqada bishan.

Marka hore, dawada waxaa lagu bixin doonaa Xarunta Kansarka ee Cross Cancer Institute ee Edmonton, waxaana la filayaa inay sidoo kale laga heli doono Xarunta Daryeelka Kansarka ee Arthur J.E. Child Comprehensive Cancer Centre dhammaadka sanadkan.

Pluvicto waa daawo lagu qaato xarun kansar, waxaana lagu bixiyaa xariiq duritaan ah (IV). Waxay ka kooban tahay radioligand, taas oo ah walax isku daraysa molecule bartilmaameedsanaya unugyada kansarka oo leh qadar yar oo shucaac ah. Radioligand-kan wuxuu ku xirmayaa unugyada kansarka prostate-ka oo leh tilmaame gaar ah, taasoo keenta in shucaaca bartilmaameedsanaya uu si sax ah u dilo unugyada kansarka.

Kahor inta aysan bukaanadu helin daawaynta, waxaa la marsiiyaa baaritaanka PET-CT si loo xaqiijiyo in unugyadoodu leeyihiin tilmaamaha gaarka ah ee lagama maarmaanka u ah daawaynta. Waxaa lagu qiyaasaa in sannad kasta qiyaastii 200 oo bukaan ah oo qaba kansarka prostate-ka heerka sare ah ay leeyihiin tilmaamahaan, taasoo ka dhigaysa kuwa ka faa'iidaysan kara daawaynta Pluvicto.

Bishii Maarso 2024, dowladda Alberta waxay ku bixisay \$5 milyan in la hirgeliyo baaraha prostate specific membrane antigen (PSMA) PET/CT, si loo baaro loona

ogaado kansarka prostate-ka ee heerka sare ah si sax ah, looguna fududeeyo bukaannada helitaanka daawaynta Pluvicto.

Xogta la xiriirta

- [Faa'idooyinka Daawooyinka Gaarka ah](#) – Barnaamijka Faa'iidada Daawada Kansarka ee Baxnaaninta Bukaannada Dibadda ([Specialized drug benefits](#) – Outpatient Cancer Drug Benefit Program)

Weydiimaha warbaahinta

[Jessi Rampton](#)

587-357-3729

Xoghayaha Saxaafadda, Caafimaadka Alberta